0
Jounce Therapeutics, Inc. Banner Image

Jounce Therapeutics, Inc. has reached its limit for free report views

Work for Jounce Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Jounce Therapeutics, Inc.

  • Ticker JNCE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Jounce Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stageMore assets from its robust discovery engine based on its Translational Science Platform. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the EMERGE Phase 2 trial. Vopratelimab will also be evaluated in the Phase 2 SELECT trial in combination with Jounce’s internal investigational PD-1 inhibitor, JTX-4014, in biomarker selected patients using TISvopra.
Jounce Therapeutics, Inc.

Most Recent Annual Report

Jounce Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Jounce Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports